Publications by authors named "Jula Inrig"

Claim this Profile
P
Proteinuria as an End Point in Clinical Trials of Focal Segmental Glomerulosclerosis.
Laura H Mariani, Howard Trachtman, Aliza Thompson, Barbara S Gillespie, Michelle Denburg, Jula K Inrig

Am J Kidney Dis· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Framework for precision medicine in focal segmental glomerulosclerosis: Translation of sparsentan-responsive genes in a rat model to kidney disease associated proteins in biofluids.
Sean Eddy, Viji Nair, John Hartman, Damian Fermin, Felix Eichinger, Jula Inrig

medRxiv· February 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Sparsentan and kidney protection: improved medullary oxygenation? - Authors' reply.
Donald Kohan, Jula Inrig, Brad H Rovin, Radko Komers

Lancet· November 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Sparsentan: the first and only non-immunosuppressive therapy for the reduction of proteinuria in IgA nephropathy.
Howard Trachtman, Radko Komers, Jula Inrig

Expert Rev Clin Immunol· June 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Focal Segmental Glomerulosclerosis Patient Baseline Characteristics in the Sparsentan Phase 3 DUPLEX Study.
Howard Trachtman, Jai Radhakrishnan, Michelle N Rheault, Charles E Alpers, Jonathan Barratt, Jula Inrig

Kidney Int Rep· April 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Status of current trials and potential future trials with sparsentan.
Howard Trachtman, Radko Komers, Jula Inrig

Expert Opin Emerg Drugs· December 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Sparsentan versus Irbesartan in Focal Segmental Glomerulosclerosis.
Michelle N Rheault, Charles E Alpers, Jonathan Barratt, Stewart Bieler, Pietro Canetta, Jula K Inrig

N Engl J Med· December 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and safety of sparsentan versus irbesartan in patients with IgA nephropathy (PROTECT): 2-year results from a randomised, active-controlled, phase 3 trial.
Brad H Rovin, Jonathan Barratt, Hiddo J L Heerspink, Charles E Alpers, Stewart Bieler, Jula K Inrig

Lancet· December 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Implications of Complete Proteinuria Remission at any Time in Focal Segmental Glomerulosclerosis: Sparsentan DUET Trial.
Howard Trachtman, Ulysses Diva, Edward Murphy, Kaijun Wang, Jula Inrig

Kidney Int Rep· October 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Sparsentan in patients with IgA nephropathy: a prespecified interim analysis from a randomised, double-blind, active-controlled clinical trial.
Hiddo J L Heerspink, Jai Radhakrishnan, Charles E Alpers, Jonathan Barratt, Stewart Bieler, Jula Inrig

Lancet· May 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
IgA Nephropathy Patient Baseline Characteristics in the Sparsentan PROTECT Study.
Jonathan Barratt, Brad Rovin, Muh Geot Wong, Charles E Alpers, Stewart Bieler, Jula Inrig

Kidney Int Rep· May 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Dietary protein intake, kidney function, and survival in a nationally representative cohort.
Yoko Narasaki, Yusuke Okuda, Linda W Moore, Amy S You, Ekamol Tantisattamo, Jula K Inrig

Am J Clin Nutr· July 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Study Design of the Phase 3 Sparsentan Versus Irbesartan (DUPLEX) Study in Patients With Focal Segmental Glomerulosclerosis.
Radko Komers, Ulysses Diva, Jula K Inrig, Andrea Loewen, Howard Trachtman

Kidney Int Rep· April 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Beware Intradialytic Hypotension: How Low Is Too Low?
Jula K Inrig

Clin J Am Soc Nephrol· October 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
There's no place like home: 35-year patient survival on home hemodialysis.
Jerry Z Yu, Connie M Rhee, Antoney Ferrey, Alex Li, Anna Jin, Jula Inrig

Semin Dial· May 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Intradialytic hypotension, blood pressure changes and mortality risk in incident hemodialysis patients.
Jason A Chou, Elani Streja, Danh V Nguyen, Connie M Rhee, Yoshitsugu Obi, Jula K Inrig

Nephrol Dial Transplant· January 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Special situations: Intradialytic hypertension/chronic hypertension and intradialytic hypotension.
Peter Noel Van Buren, Jula K Inrig

Semin Dial· November 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Comparison of Ambulatory Blood Pressure Patterns in Patients With Intradialytic Hypertension and Hemodialysis Controls.
Catherine Hompesch, Tsung-Wei Ma, Javier A Neyra, Lindsay Ripley, Guanghua Xiao, Jula Inrig

Kidney Blood Press Res· March 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Extracellular Volume Overload and Increased Vasoconstriction in Patients With Recurrent Intradialytic Hypertension.
Peter Noel Van Buren, Yunyun Zhou, Javier A Neyra, Guanghua Xiao, Wanpen Vongpatanasin, Jula Inrig

Kidney Blood Press Res· March 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Mechanisms and Treatment of Intradialytic Hypertension.
Peter Noel Van Buren, Jula K Inrig

Blood Purif· December 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Overcoming Barriers in Kidney Health-Forging a Platform for Innovation.
Peter G Linde, Patrick Archdeacon, Matthew D Breyer, Tod Ibrahim, Jula K Inrig

J Am Soc Nephrol· July 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effect of low versus high dialysate sodium concentration on blood pressure and endothelial-derived vasoregulators during hemodialysis: a randomized crossover study.
Jula K Inrig, Christopher Molina, Kristin D'Silva, Catherine Kim, Peter Van Buren

Am J Kidney Dis· March 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The landscape of clinical trials in nephrology: a systematic review of Clinicaltrials.gov.
Jula K Inrig, Robert M Califf, Asba Tasneem, Radha K Vegunta, Christopher Molina

Am J Kidney Dis· May 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cardiovascular toxicity of epoetin-alfa in patients with chronic kidney disease.
Peter A McCullough, Huiman X Barnhart, Jula K Inrig, Donal Reddan, Shelly Sapp

Am J Nephrol· October 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Peri-dialytic hypertension and hypotension: another U-shaped BP-outcome association.
Jula K Inrig

Kidney Int· October 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis